- Home
- PINE vs PRLD Comparison
PINE vs PRLD Comparison
Compare PINE & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | PRLD |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.2M | 391.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PINE | PRLD |
|---|---|---|
| Price | $19.74 | $5.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $20.10 | $5.67 |
| AVG Volume (30 Days) | 144.2K | ★ 368.5K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $60,532,000.00 | $12,140,000.00 |
| Revenue This Year | $18.63 | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $85.57 | ★ N/A |
| Revenue Growth | 15.90 | ★ 73.43 |
| 52 Week Low | $13.10 | $0.83 |
| 52 Week High | $21.99 | $5.91 |
Technical Indicators
Market Signals| Indicator | PINE | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 62.16 |
| Support Level | $18.80 | $3.92 |
| Resistance Level | $19.91 | $5.62 |
| Average True Range (ATR) | 0.52 | 0.46 |
| MACD | -0.08 | 0.11 |
| Stochastic Oscillator | 19.95 | 71.51 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.